Alps Advisors Inc. raised its position in Spark Therapeutics Inc. (NASDAQ:ONCE) by 1.4% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 39,036 shares of the company’s stock after buying an additional 547 shares during the period. Alps Advisors Inc. owned about 0.13% of Spark Therapeutics worth $2,345,000 at the end of the most recent quarter.
A number of other hedge funds have also added to or reduced their stakes in ONCE. Quantbot Technologies LP acquired a new stake in Spark Therapeutics during the second quarter worth approximately $124,000. Teacher Retirement System of Texas raised its stake in Spark Therapeutics by 14.0% in the second quarter. Teacher Retirement System of Texas now owns 2,432 shares of the company’s stock worth $124,000 after buying an additional 299 shares in the last quarter. Legal & General Group Plc raised its stake in Spark Therapeutics by 105.6% in the second quarter. Legal & General Group Plc now owns 2,714 shares of the company’s stock worth $138,000 after buying an additional 1,394 shares in the last quarter. Great West Life Assurance Co. Can raised its stake in Spark Therapeutics by 113.5% in the third quarter. Great West Life Assurance Co. Can now owns 2,675 shares of the company’s stock worth $160,000 after buying an additional 1,422 shares in the last quarter. Finally, AMG National Trust Bank acquired a new stake in Spark Therapeutics during the second quarter worth approximately $256,000. 81.69% of the stock is owned by hedge funds and other institutional investors.
Shares of Spark Therapeutics Inc. (NASDAQ:ONCE) traded up 1.65% during midday trading on Friday, reaching $56.54. 184,178 shares of the company’s stock traded hands. Spark Therapeutics Inc. has a 12 month low of $21.20 and a 12 month high of $65.99. The stock has a 50 day moving average of $53.93 and a 200-day moving average of $54.08. The stock’s market cap is $1.74 billion.
Spark Therapeutics (NASDAQ:ONCE) last announced its quarterly earnings results on Thursday, November 3rd. The company reported ($1.07) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.01) by $0.06. Spark Therapeutics had a negative net margin of 441.05% and a negative return on equity of 28.28%. The business earned $1.30 million during the quarter, compared to analyst estimates of $1.26 million. During the same quarter last year, the company posted ($0.70) earnings per share. The company’s revenue was up .0% compared to the same quarter last year. On average, equities research analysts forecast that Spark Therapeutics Inc. will post ($4.17) EPS for the current fiscal year.
ONCE has been the topic of a number of recent analyst reports. Zacks Investment Research cut shares of Spark Therapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday, August 16th. Stifel Nicolaus initiated coverage on shares of Spark Therapeutics in a research report on Friday, September 2nd. They set a “buy” rating and a $73.00 price target on the stock. Jefferies Group reissued a “hold” rating on shares of Spark Therapeutics in a research report on Friday, August 5th. Cantor Fitzgerald reissued a “buy” rating and set a $94.00 price target on shares of Spark Therapeutics in a research report on Thursday, August 11th. Finally, Wedbush reissued an “underperform” rating and set a $29.00 price target (up from $28.00) on shares of Spark Therapeutics in a research report on Wednesday, August 10th. Three research analysts have rated the stock with a sell rating, four have assigned a hold rating and seven have issued a buy rating to the company’s stock. Spark Therapeutics has a consensus rating of “Hold” and a consensus target price of $60.75.
In other news, insider Katherine A. High sold 10,000 shares of the stock in a transaction on Thursday, September 15th. The shares were sold at an average price of $60.37, for a total transaction of $603,700.00. Following the completion of the sale, the insider now directly owns 220,500 shares in the company, valued at $13,311,585. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, insider Barge Joseph La sold 3,000 shares of the stock in a transaction on Monday, October 3rd. The stock was sold at an average price of $60.14, for a total transaction of $180,420.00. Following the sale, the insider now owns 8,325 shares of the company’s stock, valued at $500,665.50. The disclosure for this sale can be found here. Insiders own 9.60% of the company’s stock.
About Spark Therapeutics
Spark Therapeutics, Inc (Spark) is engaged in developing products in the field of gene therapy. The Company focuses on treating orphan diseases. It has a pipeline of product candidates targeting multiple rare blinding conditions, hematologic disorders and neurodegenerative diseases. Its SPK-RPE65 (voretigene neparvovec) targets genetic blinding conditions known as inherited retinal dystrophies (IRDs).